Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
BENZYL PENICILLIN
Anti-infectives · Anti-infectives · Level 1
|
FLUCLOXACILLIN
Anti-infectives · Anti-infectives · Level 1
|
AMPICILLIN
Anti-infectives · Anti-infectives · Level 1
|
|---|---|---|---|
| Mechanism of action | β lactam antibiotic |
Beta lactam ring binds to penicillin binding protein (transpeptidase) and Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested Less bactericidal but stable to staph beta-lactamases |
Contains a beta lactam ring structure. Betalactam antibiotics inhibit the growth of sensitive bacteria by inactivating transpeptidase enzymes located in the bacterial cell membrane, inhibiting crosslinkage of peptidoglycans and thus impairing cell wall synthesis |
| Absorption | Orally not absorbed (need penicillin V) |
bioavailabilty 50–70% |
BA 62% |
| Distribution | CSF and bone penetration if inflammation present |
penetration into CSF occurs with inflamed meninges only |
penetration into CSF occurs with inflamed meninges only |
| Protein binding | 60% PB |
up to 95% PB |
20% PB |
| Volume of distribution | Vd <1L/kg |
Vd ~0.28 L/kg |
— |
| Metabolism | Inactive metabolite penicollic acid |
Hepatic- active metab |
Some Hepatic Metabolism |
| Excretion | 90% excreted in urine by tubular secretion |
excretion Urine (50-65% as unchanged drug) |
Mostly unchanged in urine. |
| Half-life | — | half life 0.75–1 hours, prolonged in anuria/renal impair |
— |
| Adverse Effects Toxicity | GIT– abdominal pain, N/V/D, pseudomembranous colitis, hepatitis |
Up to 10% of the population have allergies to penicillins. Due to the high |
— |
| Antimicrobial Spectrum | Narrow-Spectrum Highly bactericidal, only Targets Synergistic effects with |
narrow spectrum but is |
Moderate spectrum |
| Class Group | ANTIBIOTIC: |
ANTIBIOTIC: |
ANTIBIOTIC: |
| Indications Uses | — | useful for treating staphlococci which are resistant to benpen due to beta-lactamase activity |
— |
| Introduction | Narrow spectrum naturally occurring penicillin |
Narrow spectrum, semisynthetic anti-staphylococcal penicillin |
Betalactam |
| Legacy Cicm Level | Level 1 |
Level 1 |
Level 1 |
| Presentation | — | PO/IV. Tablet/Powder for reconstitution |
— |
| Resistance Mechanism | Resistance |
MRSA develop or acquire the gene mecA which synthesizes an additional penicillin binding protein that enables it to continue cell wall synthesis in the presence of a beta lactam drug |
Bacteria produce beta lactamases, which hydrolyse and inactivate the antibiotic Resistance |